LP Pharmaceuticals   Report issue

For profit Phase 2
Founded: Xiamen China (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2020
NCT04592198
First Marketed Drug
2017
clonidine (catapres)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Xiamen LP Pharmaceutical Co., Ltd | XIAMEN LP PHARM CO